Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Hefei Institute of Stem Cell and Regenerative Medicine (HISCRM) is a specialized biotechnology organization focused on the advancement of regenerative medicine and stem cell-based therapeutics. Founded as a strategic collaboration between the Hefei Municipal Government and the Chinese Academy of Sciences, the institute serves as a hub for translating basic stem cell research into clinical solutions. Its core technological focus includes induced pluripotent stem cell (iPSC) reprogramming, the development of organoid models for drug screening, and the engineering of cell therapies for degenerative conditions. HISCRM operates state-of-the-art facilities for cell processing and quality control, aiming to establish a standardized industrial chain for regenerative medicine in China. The institute actively engages in both independent R&D and collaborative projects with academic and industrial partners to address unmet medical needs in neurology and hepatology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hefei Institute of Stem Cell and Regenerative Medicine.